The AOM coverage discussion, however, continues to be an extremely difficult topic, as plan sponsors seek to balance the high cost of these newer medications against the sustained success of weight-loss outcomes
And are equally important markers of progress. GLP-1 therapies are not miracle drugs
[3] It is not recommended in type 1 diabetes
participants should not adjust their dose independently Antiemetics : A clinician may consider short-term antiemetic treatment if nausea is significant For concerns related to muscle mass preservation , incorporating resistance exercise and ensuring adequate dietary protein intake are evidence-based strategies that may help mitigate lean tissue loss during significant weight reduction

placebo in the fall of eGFR was better among patients with macroalbuminuria or in those with eGFR between 3060 ml/min/1.73 m2,100 and in the AWARD-7 trial the effect of dulaglutide on renal clinical outcomes and eGFR decline was more pronounced in participants with macroalbuminuria at baseline.66 Likewise, in a post hoc analysis of the LEADER study those patients who experienced a 30% reduction in albuminuria during follow-up had fewer cardiovascular and renal events,101 which confirms that a reduction in albuminuria is associated with a reduction in cardiovascular and renal events.99,102 Finally, the renal benefits of arGLP-1 appear to be additive to those of iSGLT2, which is of particular interest in patients with DKD.85,86,103 Cardiovascular and renal benefits of these drugs have been also demonstrated in real-life studies.104105 The causes of renal protection by some arGLP-1 s are unclear

Both substances are important tools for scientists studying various aspects of metabolism, muscle physiology and energy balance